A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors

摘要

This phase I trial determined that the Polo-like kinase inhibitor volasertib can be combined at the recommended single-agent dose (300 mg every 3 weeks) with nintedanib (200 mg twice a day), a triple angiokinase inhibitor, in patients with advanced solid tumors. Combination treatment demonstrated antitumor activity and a generally manageable safety profile.Volasertib is a potent and selective cell-cycle kinase inhibitor that induces mitotic arrest and apoptosis by targeting Polo-like kinases. This study determined the maximum tolerated dose (MTD) and pharmacokinetics of volasertib combined with nintedanib, a potent and orally bioavailable triple angiokinase inhibitor, in patients with advanced solid tumors.